Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mupirocin plus acidic fibroblast growth factor for nipple fissure and nipple pain in breastfeeding women
ChiCTR1800017248Phase 4Not yet recruiting
- Sponsor
- Tianjin Central Hospital of Obstetrics and Gynecology
- Start
- Aug 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of mupirocin and fibroblast growth factor 1 in cracked nipple and nipple pain (2 arms), sponsored by Tianjin Central Hospital of Obstetrics and Gynecology. Primary endpoint: Visual analogue scale. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
mupirocinfibroblast growth factor 1
03
Conditions
cracked nipplenipple pain
Beyond the preview
Go deeper on ChiCTR1800017248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017248.